SCHEMBL22026802

SCHEMBL22026802

CC(C)CC(/C=C/C(Cc1ccccc1)C(=O)O)NC(=O)OC(C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE P12821 1/20 0.52
REN P00797 4/20 0.51
MAPK1 P28482 1/20 0.51
ATM Q13315 1/20 0.50
CTSS P25774 2/20 0.48
CTSK P43235 2/20 0.48
CTSL P07711 1/20 0.48
CTSB P07858 1/20 0.48
PPARA Q07869 2/20 0.47
PPARG P37231 1/20 0.47
APP P05067 2/20 0.47
PSEN1 P49768 2/20 0.46
PSEN2 P49810 2/20 0.46
APH1B Q8WW43 2/20 0.46
NCSTN Q92542 2/20 0.46
APH1A Q96BI3 2/20 0.46
PSENEN Q9NZ42 2/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13323707 1.00 ACE (0.52) ACERENMAPK1ATMCTSS
SCHEMBL13863166 0.92 REN (0.50) ACERENMAPK1ATMCTSS
SCHEMBL25728666 0.91 REN (0.56) ACERENMAPK1ATMCTSS
SCHEMBL9659216 0.90 ACE (0.56) ACERENATMCTSSCTSK
SCHEMBL7323810 0.90 ACE (0.56) ACERENATMCTSSCTSK
SCHEMBL9659207 0.90 ACE (0.56) ACERENATMCTSSCTSK
SCHEMBL7323815 0.90 ACE (0.56) ACERENATMCTSSCTSK
SCHEMBL30022871 0.88 ACE (0.54) ACERENMAPK1ATMCTSS
SCHEMBL13323705 0.85 REN (0.50) ACERENMAPK1ATMCTSS
SCHEMBL38660770 0.84 CTSK (0.50) RENMAPK1CTSSCTSKCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11692008-B2 Preparation and uses of reactive oxygen species scavenger derivatives XWPharma Ltd. (KY) 2023-07-04 US disclosed
EP-3988561-B1 PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER XWPHARMA LTD (KY) 2023-06-07 EP disclosed
CN-115475229-A Preparation and use of active oxygen scavenger 凯瑞康宁生物工程(武汉)有限公司 2022-12-16 CN disclosed
CN-115109116-A Preparation and use of active oxygen scavenger derivatives 凯瑞康宁生物工程(武汉)有限公司 2022-09-27 CN disclosed
CN-111356699-B Preparation and use of active oxygen scavenger 凯瑞康宁生物工程(武汉)有限公司 2022-08-23 CN disclosed
CN-111278807-B Preparation and use of active oxygen scavenger derivatives 凯瑞康宁生物工程(武汉)有限公司 2022-07-22 CN disclosed
EP-3668837-B1 PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES XWPHARMA LTD (KY) 2022-07-06 EP disclosed
EP-3988561-A1 PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER XWPharma Ltd. (KY) 2022-04-27 EP disclosed
US-11312703-B2 Reactive oxygen species scavengers and use for treating diseases XWPharma Ltd. (KY) 2022-04-26 US disclosed
EP-3679051-B1 PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER XWPHARMA LTD (KY) 2021-12-29 EP disclosed
US-20210061791-A1 REACTIVE OXYGEN SPECIES SCAVENGERS AND USE FOR TREATING DISEASES XWPharma Ltd. (KY) 2021-03-04 US disclosed
US-20210047367-A1 PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES XWPharma Ltd. (KY) 2021-02-18 US disclosed
US-10889572-B2 Reactive oxygen species scavengers and use for treating diseases XW LABORATORIES INC. (KY) 2021-01-12 US disclosed
US-10858394-B2 Preparation and uses of reactive oxygen species scavenger derivatives XW LABORATORIES INC. (KY) 2020-12-08 US disclosed
CN-111356699-A Preparation and use of active oxygen scavenger 凯瑞康宁生物工程(武汉)有限公司 2020-06-30 CN disclosed
US-20200199108-A1 PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER XWPharma Ltd. (KY) 2020-06-25 US disclosed
CN-111278807-A Preparation and use of active oxygen scavenger derivatives 凯瑞康宁生物工程(武汉)有限公司 2020-06-12 CN disclosed
US-20200181194-A1 PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES XWPharma Ltd. (KY) 2020-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200181194-A1 PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES AIFM2, GPX1, GPX4 ACE 4005/4885REN 1144/4885MAPK1 902/4885
US-20210047367-A1 PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES AIFM2, GPX1, GPX4 ACE 4005/4885REN 1144/4885MAPK1 902/4885
US-10889572-B2 Reactive oxygen species scavengers and use for treating diseases GSR, TXNRD2, GPX1 ACE 1833/4885REN 280/4885MAPK1 1842/4885
US-20210061791-A1 REACTIVE OXYGEN SPECIES SCAVENGERS AND USE FOR TREATING DISEASES GSR, TXNRD2, GPX1 ACE 1833/4885REN 280/4885MAPK1 1842/4885
US-20200199108-A1 PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER GPX1, SOD1, GPX4 ACE 2524/4885REN 437/4885MAPK1 1353/4885
US-11692008-B2 Preparation and uses of reactive oxygen species scavenger derivatives AIFM2, GPX1, GPX4 ACE 4005/4885REN 1144/4885MAPK1 902/4885
US-10858394-B2 Preparation and uses of reactive oxygen species scavenger derivatives AIFM2, GPX1, GPX4 ACE 4005/4885REN 1144/4885MAPK1 902/4885
US-11312703-B2 Reactive oxygen species scavengers and use for treating diseases GSR, TXNRD2, GPX1 ACE 1833/4885REN 280/4885MAPK1 1842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.